Shukra Pharmaceuticals (NSE:SHUKRAPHAR) Margin of Safety % (DCF Earnings Based): N/A (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHUKRAPHAR Shukra Pharmaceuticals Ltd NSE:SHUKRAPHAR
61 GF Score
Price ₹41.55
GF Value ₹8.56
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Shukra Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-08-19), Shukra Pharmaceuticals's Predictability Rank is 3-Stars. Shukra Pharmaceuticals's intrinsic value calculated from the Discounted Earnings model is ₹0.00 and current share price is ₹41.55. Consequently,

Shukra Pharmaceuticals's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is N/A.

NSE:SHUKRAPHAR vs : Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shukra Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Shukra Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


NSE:SHUKRAPHAR
61GF Score
Shukra Pharmaceuticals Ltd NSE:SHUKRAPHAR
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shukra Pharmaceuticals Margin of Safety % (DCF Earnings Based) Calculation

Shukra Pharmaceuticals's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(0.00-41.55)/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

Is Shukra Pharmaceuticals (NSE:SHUKRAPHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued. The current stock price of ₹41.55 is trading 385.4% above its estimated GF Value™ of ₹8.56. GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:SHUKRAPHAR:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ₹8.56 vs. price of ₹41.55 (385.4% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the NSE:SHUKRAPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shukra Pharmaceuticals Business Description

Comparable Companies
Other Exchanges 524632:India
Address Judges Bunglow Road, Bodakdev, 3rd Floor, Dev House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
61GF Score

Get the complete analysis for NSE:SHUKRAPHAR

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹41.55
Price
₹8.56
GF Value